Developing selectively nonselective drugs for treating CNS disorders

John Gray, Bryan L. Roth

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

For the past two decades, drug discovery has been dominated by the 'magic bullet' or single molecular target-based approach. But for many diseases of the central nervous system, especially complex polygenic disorders such as schizophrenia, the most effective drugs have affinity for many molecular targets. Various methods have been recently proposed for developing so-called 'selectively nonselective drugs' or 'magic shotguns' - that is, therapeutics with more complex pharmacological profiles.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalDrug Discovery Today: Therapeutic Strategies
Volume3
Issue number4
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Magic
Central Nervous System Diseases
Firearms
Drug Discovery
Pharmaceutical Preparations
Schizophrenia
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Developing selectively nonselective drugs for treating CNS disorders. / Gray, John; Roth, Bryan L.

In: Drug Discovery Today: Therapeutic Strategies, Vol. 3, No. 4, 06.2006, p. 413-419.

Research output: Contribution to journalArticle

@article{5321896c48584f48815fd1f7b191869f,
title = "Developing selectively nonselective drugs for treating CNS disorders",
abstract = "For the past two decades, drug discovery has been dominated by the 'magic bullet' or single molecular target-based approach. But for many diseases of the central nervous system, especially complex polygenic disorders such as schizophrenia, the most effective drugs have affinity for many molecular targets. Various methods have been recently proposed for developing so-called 'selectively nonselective drugs' or 'magic shotguns' - that is, therapeutics with more complex pharmacological profiles.",
author = "John Gray and Roth, {Bryan L.}",
year = "2006",
month = "6",
doi = "10.1016/j.ddstr.2006.11.009",
language = "English (US)",
volume = "3",
pages = "413--419",
journal = "Drug Discovery Today: Therapeutic Strategies",
issn = "1740-6773",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Developing selectively nonselective drugs for treating CNS disorders

AU - Gray, John

AU - Roth, Bryan L.

PY - 2006/6

Y1 - 2006/6

N2 - For the past two decades, drug discovery has been dominated by the 'magic bullet' or single molecular target-based approach. But for many diseases of the central nervous system, especially complex polygenic disorders such as schizophrenia, the most effective drugs have affinity for many molecular targets. Various methods have been recently proposed for developing so-called 'selectively nonselective drugs' or 'magic shotguns' - that is, therapeutics with more complex pharmacological profiles.

AB - For the past two decades, drug discovery has been dominated by the 'magic bullet' or single molecular target-based approach. But for many diseases of the central nervous system, especially complex polygenic disorders such as schizophrenia, the most effective drugs have affinity for many molecular targets. Various methods have been recently proposed for developing so-called 'selectively nonselective drugs' or 'magic shotguns' - that is, therapeutics with more complex pharmacological profiles.

UR - http://www.scopus.com/inward/record.url?scp=33846173583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846173583&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2006.11.009

DO - 10.1016/j.ddstr.2006.11.009

M3 - Article

AN - SCOPUS:33846173583

VL - 3

SP - 413

EP - 419

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

SN - 1740-6773

IS - 4

ER -